<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651662</url>
  </required_header>
  <id_info>
    <org_study_id>R1979-ONC-1504</org_study_id>
    <secondary_id>2015-001697-17</secondary_id>
    <nct_id>NCT02651662</nct_id>
  </id_info>
  <brief_title>Study of Cemiplimab and REGN1979 in Patients With Lymphoma</brief_title>
  <official_title>A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, and REGN2810, an Anti-Programmed Death-1 Monoclonal Antibody, in Patients With B-Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, dose escalation study of cemiplimab and REGN1979 in&#xD;
      patients with lymphoma. The study treatment period will be from 6 to 12 months, depending on&#xD;
      how an individual patient responds to treatment. The follow-up period will be 6 months for&#xD;
      all patients.&#xD;
&#xD;
      The primary objective of the study is to assess safety, tolerability and dose-limiting&#xD;
      toxicity (DLT) of:&#xD;
&#xD;
        -  Single-agent cemiplimab in patients with lymphoma (B-NHL and HL)&#xD;
&#xD;
        -  Combination REGN1979 and cemiplimab in patients with B-NHL&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To determine a recommended dose for:&#xD;
&#xD;
        -  Cemiplimab as a single-agent in patients with lymphoma (B-NHL and HL)&#xD;
&#xD;
        -  REGN1979 and cemiplimab administered in combination in patients with B-NHL&#xD;
&#xD;
        -  To characterize the pharmacokinetic (PK) profile of cemiplimab when administered as a&#xD;
           single agent and of cemiplimab and REGN1979 when administered in combination&#xD;
&#xD;
        -  To assess the immunogenicity of cemiplimab when administered alone and the&#xD;
           immunogenicity of cemiplimab and REGN1979 when administered in combination&#xD;
&#xD;
        -  To study the preliminary antitumor activity of cemiplimab as a single agent and of the&#xD;
           combination of cemiplimab and REGN1979 in specific indications, as measured by overall&#xD;
           response rate, MRD in patients with bone marrow disease at baseline, duration of&#xD;
           response, and median progression-free survival and rates at 6 and 12 months&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 11, 2016</start_date>
  <completion_date type="Anticipated">August 19, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 19, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>TEAEs include abnormal laboratory findings and dose limiting toxicities (DLTs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of cemiplimab when given alone, and of cemiplimab and REGN1979 when given in combination</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>PK variables of cemiplimab may include, but are not limited to, the following:&#xD;
Area under the concentration-time curve (AUC) over a dosing interval, the peak concentration and last positive (quantifiable) concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity (includes response evaluation per Cheson and Lugano criteria)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Open label (cemiplimab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental cohorts will consist of multiple dose levels of cemiplimab administered intravenously (IV) every 2 weeks (Q2W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open label (cemiplimab and REGN1979)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental cohorts will consist of a single dose level of cemiplimab administered intravenously (IV) and multiple dose levels of REGN1979 administered intravenously (IV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cemiplimab</intervention_name>
    <description>Multiple dose levels administered IV Q2W</description>
    <arm_group_label>Open label (cemiplimab and REGN1979)</arm_group_label>
    <arm_group_label>Open label (cemiplimab)</arm_group_label>
    <other_name>REGN2810</other_name>
    <other_name>Libtayo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1979</intervention_name>
    <description>Single dose level of cemiplimab and multiple dose levels of REGN1979 administered IV</description>
    <arm_group_label>Open label (cemiplimab and REGN1979)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria [(Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL)]:&#xD;
&#xD;
          1. Have documented CD20+ B-cell NHL or documented HL, with active disease that is either&#xD;
             not responsive to or relapsed after prior therapy, for whom no standard of care&#xD;
             options exists.&#xD;
&#xD;
          2. Must have at least 1 bi-dimensionally measurable lesion (≥1.5 cm) documented by&#xD;
             diagnostic imaging (CT, PET-CT or MRI).&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status ≤1&#xD;
&#xD;
          4. Life expectancy of at least 6 months&#xD;
&#xD;
          5. Adequate bone marrow function&#xD;
&#xD;
          6. Adequate organ function&#xD;
&#xD;
          7. Willing and able to comply with clinic visits and study-related procedures&#xD;
&#xD;
          8. Provide signed informed consent&#xD;
&#xD;
        Key Exclusion Criteria (NHL and HL):&#xD;
&#xD;
          1. Primary central nervous system (CNS) lymphoma, or known or suspected CNS involvement&#xD;
             by nonprimary CNS NHL&#xD;
&#xD;
          2. History of or current relevant CNS pathology&#xD;
&#xD;
          3. Ongoing or recent (within 2 years) evidence of significant autoimmune disease that&#xD;
             required treatment with systemic immunosuppressive treatments, which may suggest risk&#xD;
             for iAEs&#xD;
&#xD;
          4. Prior allogeneic stem cell transplantation&#xD;
&#xD;
          5. Prior treatment with an agent that blocks the programmed death-1/ programmed&#xD;
             death-ligand 1 (PD-1/PD-L1 pathway), unless benefit was demonstrated&#xD;
&#xD;
          6. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or&#xD;
             hepatitis C infection or other uncontrolled infection&#xD;
&#xD;
          7. History of hypersensitivity to any compound in the tetracycline antibiotics group&#xD;
&#xD;
          8. Known hypersensitivity to both allopurinol and rasburicase&#xD;
&#xD;
          9. Pregnant or breastfeeding women&#xD;
&#xD;
         10. Continued sexual activity in men or women of childbearing potential who are unwilling&#xD;
             to practice adequate contraception during the study&#xD;
&#xD;
         11. Prior treatment with idelalisib&#xD;
&#xD;
        Note: Other protocol Inclusion/Exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wurttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

